Aeglea BioTherapeutics Inc (was renamed to Spyre Therapeutics (SYRE)) (AGLE) Event Aug. 04, 2022, 00:00 UTC (61% Neutral) AEGLEA BIOTHERAPEUTICS, INC. (AGLE) Reports Net Loss for 2022-06-30 Full text
Register to leave comments News bot Oct. 29, 2025, 10:47 a.m. 🏢 Aeglea BioTherapeutics Inc (was renamed to Spyre Therapeutics (SYRE)) (AGLE) - Form 10-Q Quarterly Report Quarterly financial filing submitted to the SEC 📋 Filing Information 📄 Form Type: 10-Q 📅 Filing Date: 2022-08-04 📊 Period of Report: 2022-06-30 ⏰ Accepted: N/A 📊 Key Financial Metrics (Period-over-Period Comparison) Metric Current Period Previous Period Change ($) Change (%) Trend Net Income/Loss $-6.83M $-6.83M N/A +0.00% ➡️ Total Assets $109.93M $106.71M $3.22M +3.02% ↗️ Total Liabilities $25.98M $22.55M $3.44M +15.23% 📉 Stockholders' Equity $119.02M $-301.06M $420.08M +139.54% 📈 Operating Income/Loss $-24.91M $-46.86M $21.95M +46.84% 📉 R&D Expense $25.43M $32.35M $-6.92M -21.38% 📈 Earningspersharebasic $-0.38 $-0.63 $0.25 +39.68% 📈 Earningspersharediluted $-0.38 $-0.63 $0.25 +39.68% 📈 📈 Financial Trend Analysis 🔻 Reported net loss for the period • ⚖️ Liability growth outpaced asset growth 📎 View Full 10-Q Filing on SEC.gov Access the complete official filing document
🏢 Aeglea BioTherapeutics Inc (was renamed to Spyre Therapeutics (SYRE)) (AGLE) - Form 10-Q Quarterly Report
📋 Filing Information
Key Financial Metrics (Period-over-Period Comparison)
Financial Trend Analysis
🔻 Reported net loss for the period • ⚖️ Liability growth outpaced asset growth
📎 View Full 10-Q Filing on SEC.gov
Access the complete official filing document